Advertisement

Polypharmacy in Osteoporosis Treatment

  • Megan McConnell
    Correspondence
    Corresponding author.
    Affiliations
    UCLA Division of Endocrinology, Diabetes, and Hypertension, 10833 Le Conte Avenue, CHS 57-145, Los Angeles, CA 90095, USA
    Search for articles by this author
  • Author Footnotes
    1 Present address: 10945 Le Cone Avenue, Peter B. Ueberroth Building, Suite 2339, Los Angeles, CA 90095.
    Albert Shieh
    Footnotes
    1 Present address: 10945 Le Cone Avenue, Peter B. Ueberroth Building, Suite 2339, Los Angeles, CA 90095.
    Affiliations
    Department of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, CHS 57-145, Los Angeles, CA 90095, USA
    Search for articles by this author
  • Author Footnotes
    1 Present address: 10945 Le Cone Avenue, Peter B. Ueberroth Building, Suite 2339, Los Angeles, CA 90095.
Published:September 13, 2022DOI:https://doi.org/10.1016/j.cger.2022.05.011

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Harvey N.C.
        • Curtis E.M.
        • Dennison E.M.
        • et al.
        The epidemiology of osteoporotic fractures.
        in: Primer on the metabolic bone diseases and disorders of mineral metabolism. 2018: 398-404
        • Fulton M.M.
        • Riley Allen E.
        Polypharmacy in the elderly: a literature review.
        J Am Acad Nurse Pract. 2005; 17: 123-132
        • Mortazavi S.S.
        • Shati M.
        • Keshtkar A.
        • et al.
        Defining polypharmacy in the elderly: a systematic review protocol.
        BMJ Open. 2016; 6: e010989
        • Tinetti M.E.
        • Bogardus S.T.
        • Agostini J.V.
        Potential pitfalls of disease-specific guidelines for patients with multiple conditions.
        N Engl J Med. 2004; 351: 2870-2874
        • Lai S.W.
        • Liao K.F.
        • Liao C.C.
        • et al.
        Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study.
        Medicine (Baltimore). 2010; 89: 295-299
        • Park H.-Y.
        • Kim S.
        • Sohn H.S.
        • et al.
        The association between polypharmacy and hip fracture in osteoporotic women: a nested case–control study in South Korea.
        Clin Drug Invest. 2019; 39: 63-71
        • Pan H.H.
        • Li C.Y.
        • Chen T.J.
        • et al.
        Association of polypharmacy with fall-related fractures in older Taiwanese people: age- and gender-specific analyses.
        BMJ Open. 2014; 4: e004428
        • Yeam C.T.
        • Chia S.
        • Tan H.C.C.
        • et al.
        A systematic review of factors affecting medication adherence among patients with osteoporosis.
        Osteoporos Int. 2018; 29: 2623-2637
        • Siris E.S.
        • Selby P.L.
        • Saag K.G.
        • et al.
        Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
        Am J Med. 2009; 122: S3-S13
        • Penning-van Beest F.J.
        • Erkens J.A.
        • Olson M.
        • et al.
        Loss of treatment benefit due to low compliance with bisphosphonate therapy.
        Osteoporos Int. 2008; 19: 511-517
        • Weycker D.
        • Macarios D.
        • Edelsberg J.
        • et al.
        Compliance with osteoporosis drug therapy and risk of fracture.
        Osteoporos Int. 2007; 18: 271-277
        • Yu S.
        • Burge R.T.
        • Foster S.A.
        • et al.
        The impact of teriparatide adherence and persistence on fracture outcomes.
        Osteoporos Int. 2012; 23: 1103-1113
        • Solomon D.H.
        • Avorn J.
        • Katz J.N.
        • et al.
        Compliance with osteoporosis medications.
        Arch Intern Med. 2005; 165: 2414-2419
        • Fried T.R.
        • O'Leary J.
        • Towle V.
        • et al.
        Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review.
        J Am Geriatr Soc. 2014; 62: 2261-2272
        • Dhalwani N.N.
        • Fahami R.
        • Sathanapally H.
        • et al.
        Association between polypharmacy and falls in older adults: a longitudinal study from England.
        BMJ Open. 2017; 7: e016358
        • Camacho P.M.
        • Petak S.M.
        • Binkley N.
        • et al.
        American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary.
        Endocr Pract. 2020; 26: 564-570
        • Compston J.E.
        • McClung M.R.
        • Leslie W.D.
        Osteoporosis.
        Lancet. 2019; 393: 364-376
        • Cummings S.R.
        • Black D.M.
        • Thompson D.E.
        • et al.
        Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
        JAMA. 1998; 280: 2077-2082
        • Black D.M.
        • Cummings S.R.
        • Karpf D.B.
        • et al.
        Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
        Lancet. 1996; 348: 1535-1541
        • Harris S.T.
        • Watts N.B.
        • Genant H.K.
        • et al.
        Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
        JAMA. 1999; 282: 1344-1352
        • McClung M.R.
        • Geusens P.
        • Miller P.D.
        • et al.
        Effect of risedronate on the risk of hip fracture in elderly women.
        N Engl J Med. 2001; 344: 333-340
        • Black D.M.
        • Delmas P.D.
        • Eastell R.
        • et al.
        Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
        N Engl J Med. 2007; 356: 1809-1822
        • Lyles K.W.
        • Colón-Emeric C.S.
        • Magaziner J.S.
        • et al.
        Zoledronic acid and clinical fractures and mortality after hip fracture.
        N Engl J Med. 2007; 357: 1799-1809
        • Cummings S.R.
        • San Martin J.
        • McClung M.R.
        • et al.
        Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
        N Engl J Med. 2009; 361: 756-765
        • Bone H.G.
        • Wagman R.B.
        • Brandi M.L.
        • et al.
        10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
        Lancet Diabetes Endocrinol. 2017; 5: 513-523
        • Qaseem A.
        • Forciea M.A.
        • McLean R.M.
        • et al.
        Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the american college of physicians.
        Ann Intern Med. 2017; 166: 818-839
        • Eastell R.
        • Rosen C.J.
        • Black D.M.
        • et al.
        Pharmacological management of osteoporosis in postmenopausal women: an endocrine society∗ clinical practice guideline.
        J Clin Endocrinol Metab. 2019; 104: 1595-1622
        • Chesnut 3rd, C.H.
        • Skag A.
        • Christiansen C.
        • et al.
        Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
        J Bone Miner Res. 2004; 19: 1241-1249
        • Barrionuevo P.
        • Kapoor E.
        • Asi N.
        • et al.
        Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis.
        J Clin Endocrinol Metab. 2019; 104: 1623-1630
        • Cummings S.R.
        • Ferrari S.
        • Eastell R.
        • et al.
        Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension.
        J Bone Miner Res. 2018; 33: 190-198
        • Neer R.M.
        • Arnaud C.D.
        • Zanchetta J.R.
        • et al.
        Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
        N Engl J Med. 2001; 344: 1434-1441
        • Miller P.
        • Hattersley G.
        • Riis B.
        • et al.
        Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial.
        JAMA. 2016; 316: 722-733
        • Cosman F.
        • Crittenden D.B.
        • Adachi J.D.
        • et al.
        Romosozumab treatment in postmenopausal women with osteoporosis.
        N Engl J Med. 2016; 375: 1532-1543
        • Saag K.G.
        • Petersen J.
        • Brandi M.L.
        • et al.
        Romosozumab or alendronate for fracture prevention in women with osteoporosis.
        N Engl J Med. 2017; 377: 1417-1427
        • McClung M.R.
        • Grauer A.
        • Boonen S.
        • et al.
        Romosozumab in postmenopausal women with low bone mineral density.
        N Engl J Med. 2014; 370: 412-420
        • Cummings S.R.
        • McCulloch C.
        Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab.
        Osteoporos Int. 2020; 31: 1019-1021
        • Kendler D.L.
        • Marin F.
        • Zerbini C.A.F.
        • et al.
        Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
        Lancet. 2018; 391: 230-240
        • Vilaca T.
        • Schini M.
        • Harnan S.
        • et al.
        The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: a systematic review and meta-analysis update.
        Bone. 2020; 137: 115457
        • Khan K.S.
        • Andersen H.
        The impact of diabetic neuropathy on activities of daily living, postural balance and risk of falls - a systematic review.
        J Diabetes Sci Technol. 2021; 16: 289-294
        • Hidayat K.
        • Fang Q.L.
        • Shi B.M.
        • et al.
        Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies.
        Osteoporos Int. 2021; 32: 1693-1704
        • Díez-Pérez A.
        • Marin F.
        • Eriksen E.F.
        • et al.
        Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis.
        Bone. 2019; 120: 1-8
        • Eriksen E.F.
        • Keaveny T.M.
        • Gallagher E.R.
        • et al.
        Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis.
        Bone. 2014; 67: 246-256
        • Johansson H.
        • Siggeirsdóttir K.
        • Harvey N.C.
        • et al.
        Imminent risk of fracture after fracture.
        Osteoporos Int. 2017; 28: 775-780
        • Unson C.G.
        • Siccion E.
        • Gaztambide J.
        • et al.
        Nonadherence and osteoporosis treatment preferences of older women: a qualitative study.
        J Women's Health (2002). 2003; 12: 1037-1045
        • Reid I.R.
        • Horne A.M.
        • Mihov B.
        • et al.
        Fracture prevention with zoledronate in older women with osteopenia.
        N Engl J Med. 2018; 379: 2407-2416
        • Grey A.
        • Bolland M.J.
        • Horne A.
        • et al.
        Five years of anti-resorptive activity after a single dose of zoledronate — results from a randomized double-blind placebo-controlled trial.
        Bone. 2012; 50: 1389-1393
        • Grey A.
        • Horne A.
        • Gamble G.
        • et al.
        Ten years of very infrequent zoledronate therapy in older women: an open-label extension of a randomized trial.
        J Clin Endocrinol Metab. 2020; 105: dgaa062